[Tamoxifen, endometrial cancer and levonorgestrel intra-uterine device].
Although the adjuvant tamoxifen benefit/risk rate is unquestionable in breast cancer treatment, the increase of endometrial cancer in chemoprevention is about to be a real problem. In the studies currently published metrorragia in the main signal. Levonogestrel intra-uterine device has not proved its efficacy for the decrease of this risk.
Espié
M
M
Centre des maladies du sein, hôpital Saint-Louis, Paris, France. marc.espie@sls.ap-hop-paris.fr
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D004717:Endometrium / Q000187:drug effects*; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage*; D008796:Metrorrhagia / Q000139:chemically induced / Q000517:prevention & control; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D016912:Levonorgestrel